Using data from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, a team from the CDC investigated lifetime HIV risk in the United States.
Persistent disparities in the lifetime risk of an HIV diagnosis between females and males, as well as among races and ethnicities, highlight the ongoing need to step up education and prevention efforts in the United States, CDC researchers noted in a presentation at this year’s Conference on Retroviruses and Opportunistic Infections.
These investigators utilized data on HIV diagnosis, mortality, and census population from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, respectively. Probability of an HIV diagnosis at any age was calculated via HIV diagnoses and non-HIV deaths from 2017 to 2019 and compared with similar data from 2010 through 2014.
“Estimating the lifetime risk may be a useful tool for clinicians, partners, and policy makers when describing the burden of HIV since it can be more readily understood by the public,” the authors wrote. “Estimates of lifetime risk are used to compare the burden of disease across populations.”
Overall, their numbers show a 1 in 120 lifetime risk of an HIV diagnosis for 2017 to 2019 vs 1 in 106 for 2010 to 2014, which is an 11% improvement.
When comparing this outcome between females and males, the risk was lower for females (1 in 309) and greater for males (1 in 76), so that the latter had a 4 times greater risk of an HIV diagnosis.
Also, when stratifying risk by race, females had a universal lower lifetime risk of HIV vs males:
Further, when comparing 2010 to 2014 and 2017 to 2019, lifetime risk was shown to be down for most groups. The exceptions were males of American Indian/Alaska Native, Hispanic/Latino, and Native Hawaiian/other Pacific Islander descent and White females.
Breaking the findings down by state and jurisdiction, the highest overall risks were seen in Washington, DC (1 in 39); followed by Georgia (1 in 59); Florida (1 in 63); Louisiana (1 in 69); Nevada (1 in 84); and Maryland (1 in 85). The lowest risks were in Vermont (1 in 515), New Hampshire (1 in 533), Montana (1 in 536), Maine (1 in 584), Idaho (1 in 624), and Wyoming (1 in 655).
When summing the investigators’ findings, lead author Sonia Singh, PhD, from the CDC’s Division of HIV Prevention, noted that their findings assume “the rate of infection will continue [and] that prevention efforts work,” as evidenced by the decline seen between the 2 periods.
However, there is still need for continued progress in HIV prevention and treatment because of the ongoing risk disparities.
Reference
Singh S, Hu X, Hess K. Estimating the lifetime risk of a diagnosis of HIV infection in the United States. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; Virtual. Abstract 43. https://www.croiconference.org/abstract/estimating-the-lifetime-risk-of-a-diagnosis-of-hiv-infection-in-the-united-states/
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More